WO2019103475A2 - Kit de génotypage hla utilisant une amplification en chaîne par polymérase en temps réel - Google Patents

Kit de génotypage hla utilisant une amplification en chaîne par polymérase en temps réel Download PDF

Info

Publication number
WO2019103475A2
WO2019103475A2 PCT/KR2018/014407 KR2018014407W WO2019103475A2 WO 2019103475 A2 WO2019103475 A2 WO 2019103475A2 KR 2018014407 W KR2018014407 W KR 2018014407W WO 2019103475 A2 WO2019103475 A2 WO 2019103475A2
Authority
WO
WIPO (PCT)
Prior art keywords
hla
seq
analysis
primers
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/014407
Other languages
English (en)
Korean (ko)
Other versions
WO2019103475A3 (fr
Inventor
고웅열
김주형
고아라
이은지
임희경
김원동
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osang HealthCare Co Ltd
Original Assignee
Infopia Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infopia Co Ltd filed Critical Infopia Co Ltd
Publication of WO2019103475A2 publication Critical patent/WO2019103475A2/fr
Publication of WO2019103475A3 publication Critical patent/WO2019103475A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2531/00—Reactions of nucleic acids characterised by
    • C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
    • C12Q2531/113—PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2561/00—Nucleic acid detection characterised by assay method
    • C12Q2561/113—Real time assay

Definitions

  • the present invention relates to an HLA allele test kit using real-time PCR. More particularly, the present invention relates to a method for detecting an HLA allele gene which enables detection of at least one HLA allele selected from HLA-A, HLA-B, HLA-DRB1, HLA-C, HLA-DQB1 and HLA- Kit.
  • HLA Human Leukocyte Antigen
  • HLA-A, HLA-B, HLA-B, and HLA-DRB1 are 3,968, 4,828, 3,579, 2,376, HLA-DQB1 and HLA-DQA1 were found to be 1,142 and 94, respectively (IMGT / HLA Database, Release 3.29.0).
  • HLA testing methods include serotyping by antibody-antigen reaction and molecular typing to determine the difference in HLA gene sequence.
  • Serologic methods are currently using molecular biologic methods worldwide because of the complexity of test methods and the relatively low reliability of results compared to molecular methods.
  • PCR-SSP sequence specific primers
  • PCR-SSOP Sequence Specific Oligonucleotide Probes
  • PCR-SBT sequence-based oligonucleotide probes
  • PCR-SSP method which is similar to this technique, has the disadvantage of using a large number of tubes to perform HLA test in a way that only one single base can be seen in one tube. Therefore, multiplex PCR method There has also been a continuing demand for demand.
  • Another object of the present invention is to provide an HLA allele test kit capable of detecting two or more of the HLA alleles HLA-A, HLA-B and HLA-DRB1 in one well of a kit by real-time PCR.
  • Another object of the present invention is to provide an HLA allele test kit capable of detecting HLA-C, HLA-DQB1 and HLA-DQA1.
  • the HLA allele testing kit of the present invention comprises an HLA allele for at least one gene selected from HLA-A, HLA-B, HLA-DRB1, HLA-C, HLA-DQB1 and HLA- A primer set capable of specifically amplifying by real-time PCR; And a probe capable of probing a product amplified by the real-time PCR, wherein the HLA allele test kit comprises HLA-C, HLA-DQB1 and HLA-DQA1, And alleles are amplified specifically by real-time PCR.
  • the HLA allele test kit comprises one or more genes selected from HLA-A, HLA-B, HLA-DRB1, HLA-C, HLA-DQB1 and HLA- And can be specifically amplified by real-time PCR.
  • HLA allele according to any one of the above 1 to 2, wherein the HLA allele is HLA-A * 01, HLA-A * 02, HLA-A * 03, HLA-A * 11, HLA- , HLA-A * 25, HLA-A * 26, HLA-A * 29, HLA-A * 30, HLA-A * 31, HLA-
  • the antibody comprises at least one of -A * 36, HLA-A * 43, HLA-A * 66, HLA-A * 68, HLA-A * 69, HLA- -A allele;
  • An HLA-DQB1 allele comprising at least one of HLA-DQBl * 02, HLA-DQBl * 03, HLA-DQBl * 04, HLA-DQBl * 05 and HLA-DQBl * 06;
  • An HLA-DQA1 allele comprising at least one of HLA-DQA1 * 01, HLA-DQA1 * 02, HLA-DQA1 * 03, HLA-DQA1 * 04, HLA-DQA1 * 05 and HLA-DQA1 * 06; ≪ / RTI >
  • the probe may include one or more of SEQ ID NO: 303 to SEQ ID NO: 329.
  • the set of primers for HLA-A gene analysis may comprise one or more of the following sets:
  • the set of primers for HLA-B gene analysis may comprise one or more of the following sets:
  • Set 23-1 set 24-1, set 25-1, set 26-1, set 27-1, set 28-1, set 29-1, set 30-1, set 31-1, set 32-1, Set 33-1, set 34-1, set 35-1, set 36-1, set 37-1, set 38-1, set 39-1, set 40-1, set 41-1, set 42-1, Set 43-1, set 44-1, set 45-1 and set 46-1.
  • the set of primers for HLA-C gene analysis comprises one or more of the following sets:
  • the set of primers for HLA-DQA1 gene analysis comprises one or more of the following sets:
  • the HLA allele discriminating method of the present invention comprises the steps of obtaining DNA from a sample, real-time PCR using the HLA allele test kit according to the above Examples 1 to 11 according to the present invention, and And reading the result of the real-time PCR reaction to determine the HLA allele.
  • the present invention relates to a method for detecting two or more HLA alleles HLA-A, HLA-B, HLA-DRB1, HLA-C, HLA-DQB1 and HLA- A gene test kit was provided.
  • the present invention provides an HLA allele test kit capable of detecting two or more of the HLA alleles HLA-A, HLA-B and HLA-DRB1 in one well of the kit by real-time PCR.
  • the present invention provides an HLA allele test kit capable of detecting HLA-C, HLA-DQB1, and HLA-DQA1.
  • the HLA allele test kit of the present invention is characterized in that the HLA allele for one or more genes selected from among HLA-A, HLA-B, HLA-DRB1, HLA-C, HLA-DQB1 and HLA- A set of primers that can be amplified in vivo; And a probe set capable of probing the product amplified by the real-time PCR.
  • the HLA allele test kit may comprise a set of primers that specifically amplify the HLA allele for one or more genes selected from among HLA-C, HLA-DQB1, and HLA-DQA1 by real-time PCR have.
  • the HLA allele test kit further comprises a primer set that specifically amplifies the HLA allele for one or more genes selected from among HLA-A, HLA-B, and HLA-DRB1 by real-time PCR can do.
  • the HLA allele testing kit may comprise a set of primers that specifically amplify the HLA allele for one or more genes selected from among HLA-A, HLA-B, and HLA-DRBl by real-time PCR have.
  • the HLA allele test kit further comprises a set of primers specifically amplifying the HLA allele for one or more genes selected from among HLA-C, HLA-DQB1 and HLA-DQA1 by real-time PCR .
  • the primer set of primers used in the present invention is as follows:
  • SEQ ID NO: 2 TCTGTGAGTGGGCCTTCAT
  • SEQ ID NO: 4 CCTTCCCGTTCTCCAGGTG
  • SEQ ID NO: 6 CCGTCCCAATACTCCGGA
  • SEQ ID NO: 8 TAGCGCGCTCCAGCTTGT
  • SEQ ID NO: 10 CCACTCCACGCACGTGCCA
  • SEQ ID NO: 12 CAGTCTGTGTGTTGGTCTTGA
  • SEQ ID NO: 14 GCCCTCCAGGTAGGCTCTCT
  • SEQ ID NO: 16 CAGTCTGTGTGTTGGTCTTGA
  • SEQ ID NO: 18 CCTCCAGGTAGGCTCTCTG
  • SEQ ID NO: 20 GTCAGTCTGTGCCTTGGC
  • SEQ ID NO: 22 CGCGATCCGCAGGCTCT
  • SEQ ID NO: 24 CCGGGGTCACTCACCGT
  • SEQ ID NO: 26 CCAGGTATCTGCGGAGCGA
  • SEQ ID NO: 28 CTTCACATTCCGTGTCTGCA
  • SEQ ID NO: 30 CCTCCAGGTAGGCTCTGTCC
  • SEQ ID NO: 32 CCGGGGTCACTCACCGT
  • SEQ ID NO: 34 CCTCCAGGTAGGCTCTGTCC
  • SEQ ID NO: 36 TCTGTGAGTGGGCCTTCAC
  • SEQ ID NO: 38 CCAGGTATCTGCGGAGCGA
  • SEQ ID NO: 40 GCGCGATCCGCAGGCTCT
  • SEQ ID NO: 42 CTTCACATTCCGTGTGTTCCG
  • SEQ ID NO: 44 GGAGCCACTCCACGCACAG
  • SEQ ID NO: 48 CTTGTAGTAGCGGAGCGCGA
  • SEQ ID NO: 50 GGTCCCAATACTCAGGCCT
  • SEQ ID NO: 52 CCTCCAGGTAGGCTCTGTCC
  • SEQ ID NO: 54 GAGCCACTCCACGCACGT
  • SEQ ID NO: 56 CTTGTAGTAGCGGAGCGCGA
  • SEQ ID NO: 58 GGTATCTGCGGAGCCCG
  • SEQ ID NO: 60 GAGGTATTTCCACACCGCCA
  • SEQ ID NO: 61 CGCTGTCGAACCTCACGAACA
  • SEQ ID NO: 64 CCTTCATATTCCGTGTCTGCA
  • SEQ ID NO: 65 GAGCCACTCCACGCACGT
  • SEQ ID NO: 68 CCTCCAGGTAGGCTCTCAA
  • SEQ ID NO: 70 GAGCAGGGTCCGCAGGTC
  • SEQ ID NO: 72 CAGGGTCCCCAGGTCCA
  • SEQ ID NO: 74 CCTCCAACTTGCGCTGGGA
  • SEQ ID NO: 76 TCCCCAGGTTCGCTCGGTT
  • SEQ ID NO: 78 AGCGCGCTCCAGCTTGT
  • SEQ ID NO: 80 TCTCAACTGCTCCGCCACAC
  • SEQ ID NO: 82 CTCCTTCCTCGGACTCGT
  • SEQ ID NO: 83 GGCTCCTTCCTCGGACTCGT
  • SEQ ID NO: 85 CCACTCGGTCAGTCTGTGAC
  • SEQ ID NO: 87 CCTCCAGGTAGGCTCTGTC
  • SEQ ID NO: 90 CCGCTCGTCTTCCAGGAT
  • SEQ ID NO: 94 TCCACCGCGGCCCGCGC
  • SEQ ID NO: 96 CTGTGCCTGGCGCTTGTACT
  • SEQ ID NO: 100 TGTGCCTGGGCCTTGTA
  • SEQ ID NO: 102 GCAGTAGTTGTCCACCCGGC
  • SEQ ID NO: 104 GGTCTTGTAGATCTGTGTGTTC
  • SEQ ID NO: 105 GGTCTTGAAGATCTGTGTGTTC
  • SEQ ID NO: 106 GGTCTTGGAGATCTGTGTGTTC
  • SEQ ID NO: 107 GGTCTTGCAGATCTGTGTGTTC
  • SEQ ID NO: 111 CACGAGTCCGAGGATGGC
  • SEQ ID NO: 112 TGGTCTTGGAGATCTGTGTCTC
  • SEQ ID NO: 116 TGGTTGTAGTAGCGGAGCGC
  • SEQ ID NO: 118 TGCAGTAGGTGTCCACCAG
  • SEQ ID NO: 121 AGTCTGTGTGTTGGTCTTGG
  • SEQ ID NO: 125 GTCTGTGTGTTGGTCTTGTAG
  • SEQ ID NO: 127 GCTGCACTGTGAAGCTCTCAC
  • SEQ ID NO: 129 TCTGTGCCTGGGCCTTGTA
  • SEQ ID NO: 134 TGGCCTTGCAGATCTGTGTCTC
  • SEQ ID NO: 136 CTGTTCCAGGACTCGGCGA
  • SEQ ID NO: 138 GTTCCGCAGGCTCTCTCGGTA
  • SEQ ID NO: 140 CCCGCTCGTCTTCCAGGAT
  • SEQ ID NO: 148 GTTGTAGTAGCGGAGCGCGG
  • SEQ ID NO: 149 GTTGTAGTAGCGGAGCGCGA
  • SEQ ID NO: 153 TCTGCGCGGAGGCCTTCAT
  • SEQ ID NO: 155 CACCTCGGCCCGCCTCC
  • SEQ ID NO: 159 CACCGCGGCCCGCCTCT
  • SEQ ID NO: 161 CCCAATACTCCGGCCCCTCT
  • SEQ ID NO: 163 CTGTTCCAGTGCTCCGCAG
  • SEQ ID NO: 165 CCGCGGGTATAACCAGTTA
  • SEQ ID NO: 166 AGCCACTCCACGCACAG
  • SEQ ID NO: 167 AGCGACTCCACGCACAG
  • SEQ ID NO: 171 GGAGCCACTCCACGCACAG
  • SEQ ID NO: 173 GCTYACCTCGCCKCTGCAC
  • SEQ ID NO: 175 GGAGCCACTCCACGCACGT
  • SEQ ID NO: 177 TCTGCAGTAGGTGTCCACCAG
  • SEQ ID NO: 179 CGCGGGCATGACCAGTTC
  • SEQ ID NO: 180 CACGTGCCCTCCAGGTAGGT
  • SEQ ID NO: 182 GCTGCACTGTGAAGCTCTCCA
  • SEQ ID NO: 184 GGAGCCACTCCACGCACAG
  • SEQ ID NO: 186 GCAGTAATTGTCCACCCGGC
  • SEQ ID NO: 187 GCAGTAATTGTCCACCTGGC
  • SEQ ID NO: 189 TGAGGTATTTCCACACCGCCA
  • SEQ ID NO: 190 TGAGGTATTTCGACACCGCCA
  • SEQ ID NO: 191 TGTAGTAGCCGCGCAGGT
  • SEQ ID NO: 193 CTGCACTGTGAAGCTCTCCA
  • SEQ ID NO: 195 CGCGGGTATGACCAGTC
  • SEQ ID NO: 196 GAGCCACTCCACGCACAG
  • SEQ ID NO: 199 CCGCTGCACTGTGAAGCTCT
  • SEQ ID NO: 201 TGTGCCTGGGCCTTGTA
  • SEQ ID NO: 203 GACGACACGCTGTTCGTGA
  • SEQ ID NO: 204 GACGACACCCAGTTCGTGA
  • SEQ ID NO: 205 GACGGCACCCAGTTCGTGA
  • SEQ ID NO: 206 CGCTCTGGTTGTAGTAGCG
  • SEQ ID NO: 208 GACGACACGCTGTTCGTGA
  • SEQ ID NO: 209 GACGACACCCAGTTCGTGA
  • SEQ ID NO: 210 GACGGCACCCAGTTCGTGA
  • SEQ ID NO: 211 CGCTCTGGTTGTAGTAGCC
  • SEQ ID NO: 215 AGCCACTCCACGCACTC
  • SEQ ID NO: 217 AGCGTCTCCTTCCCATTCTT
  • SEQ ID NO: 219 AGCCATACATCCTCTGGAT
  • SEQ ID NO: 221 CCGGGGTCACTCACCGG
  • SEQ ID NO: 223 AGCGTCTCCTTCCCATTCTT
  • SEQ ID NO: 225 CTGCTCCACCCACGGCT
  • SEQ ID NO: 227 CGCGCGCTGCAGCGTCTT
  • SEQ ID NO: 229 GCGCAGTTTCCGCAGGT
  • SEQ ID NO: 231 GCGCAGTTTCCGCAGGT
  • SEQ ID NO: 233 CCACTGCCCCTGGTACCT
  • SEQ ID NO: 237 CACCCTCCAGTGGATGTGT
  • SEQ ID NO: 238 GAGCCGCCGTGTCCGCA
  • SEQ ID NO: 240 AGGACCTGCGCTCCTGGATT
  • SEQ ID NO: 241 CCTCCAGGTAGGCTCTCCA
  • SEQ ID NO: 243 CCTGCTCCACCCATGGCG
  • SEQ ID NO: 245 CTGTGCCTGGCGCTTGTAG
  • SEQ ID NO: 247 GCCCTCCTGGTAGGCTCTCT
  • SEQ ID NO: 249 TCCCGTTCTCCAGGTATCC
  • SEQ ID NO: 251 GCGCAGTTTCCGCAGGT
  • SEQ ID NO: 253 CCCACTGCCCCTGGTACCC
  • SEQ ID NO: 255 CCAGGTATCTGCGGAGCCA
  • SEQ ID NO: 257 GCTCTTCTCCAGAAGGCACCAC
  • SEQ ID NO: 259 CGTGCGGAGCTCCAACTG
  • SEQ ID NO: 261 TGGTAGTTGTGTCTGCATACG
  • SEQ ID NO: 263 CCCGCGGTACGCCACCTC
  • SEQ ID NO: 265 CCGCGGAACGCCACCTC
  • SEQ ID NO: 267 CCGCGGAACGCCACCTC
  • SEQ ID NO: 269 TGCACACCCTGTCCACCG
  • SEQ ID NO: 270 TGCACACCGTGTCCAACTC
  • SEQ ID NO: 272 CGTGCGGAGCTCCAACTG
  • SEQ ID NO: 274 CTGTTCCAGTACTCGGCGG
  • SEQ ID NO: 276 CTGTTCCAGTACTCGGCGT
  • SEQ ID NO: 278 CCCCTGCGGCGTCACCGCG
  • SEQ ID NO: 280 TGGTAGTTGTGTCTGCATACG
  • SEQ ID NO: 282 CTGTTCCAGTACTCGGCGG
  • SEQ ID NO: 284 TGCACACCGTGTCCAACTC
  • SEQ ID NO: 286 TGCACACCGTGTCCAACTC
  • SEQ ID NO: 288 GTTTTGCCACAGCCATGTTTC
  • SEQ ID NO: 290 ATGATGTTCAAGTTGTGTTTTGCC
  • SEQ ID NO: 292 TGTTCAAGTTGTGTTTTGCC
  • SEQ ID NO: 294 CAGGATGTTCAAGTTATGTTTTAGC
  • SEQ ID NO: 296 TAGAGTTGGAGCGTTTAATCAC
  • SEQ ID NO: 298 CAGGATGTTCAAGTTGTGTTTTGT
  • SEQ ID NO: 300 GAGTTGGAGCGTTTAATCAGAC
  • SEQ ID NO: 302 CAGGATGTTCAAGTTGTGTTTTGT
  • the HLA-DQB1 allele that can be analyzed by the kit of the present invention may include one or more of HLA-DQB1 * 02, HLA-DQB1 * 03, HLA-DQB1 * 04, HLA-DQB1 * 05, have.
  • HLA-DQA1 allele that can be analyzed by the kit of the present invention is HLA-DQA1 * 01, HLA-DQA1 * 02, HLA-DQA1 * 03, HLA-DQA1 * 04, HLA- And may include one or more.
  • a set of primers for HLA-A gene analysis is set 1-1, set 2-1, set 3-1, set 4-1, set 5-1, set 6, set 7-1, set 8-1, set 9 -1, set 10-1, set 11, set 12-1, set 13-1, set 14-1, set 15-1, set 16-1, set 17, set 18-1, set 19-1, set 20-1, a set 21-1, and a set 22-1.
  • the initial set for analysis of HLA-A * 01 may include one or more of set 1-1, set 4-1, set 7-1, set 9-1, set 16-1, set 17.
  • the set of primers for analysis of HLA-A * 01 may comprise one or more of the following combinations:
  • the initial set for analysis of HLA-A * 02 is set 2-1, set 3-1, set 5-1, set 9-1, set 11, set 13-1, set 15-1, set 17, set 18 -1, set 22-1.
  • the set of primers for analysis of HLA-A * 02 may comprise one or more of the following combinations:
  • the initial set for analysis of HLA-A * 03 is set 2-1, set 3-1, set 4-1, set 9-1, set 15-1, set 16-1, set 17, set 19-1, Set 22-1. ≪ / RTI >
  • the set of primers for analysis of HLA-A * 03 may comprise one or more of the following combinations;
  • the primer set for analysis of HLA-A * 11 includes one or more of set 4-1, set 5-1, set 7-1, set 9-1, set 15-1, set 17, set 22-1 .
  • the set of primers for analysis of HLA-A * 11 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 23 may include one or more of set 16-1, set 17, set 21-1.
  • the set of primers for analysis of HLA-A * 23 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 24 may include one or more of set 3-1, set 4-1, set 5-1, set 9-1, set 17, set 21-1.
  • the set of primers for analysis of HLA-A * 24 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-A * 25 can include one or more of set 6, set 7-1, set 9-1, set 11, set 13-1, set 17, set 22-1.
  • the set of primers for analysis of HLA-A * 25 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-A * 26 may include one or more of set 7-1, set 9-1, set 13-1, set 17, set 22-1.
  • the set of primers for analysis of HLA-A * 26 may comprise one or more of the following combinations;
  • the primer set for analysis of HLA-A * 29 includes one or more of set 8-1, set 9-1, set 15-1, set 16-1, set 17, set 19-1, set 21-1 .
  • the set of primers for analysis of HLA-A * 29 may comprise one or more of the following combinations;
  • the primer set for analysis of HLA-A * 30 includes one or more of set 2-1, set 3-1, set 4-1, set 10-1, set 15-1, set 17, set 22-1 .
  • the set of primers for analysis of HLA-A * 30 may comprise one or more of the following combinations;
  • a primer set for analysis of HLA-A * 31 may include one or more of set 9-1, set 14-1, set 15-1, set 17, set 21-1.
  • the set of primers for analysis of HLA-A * 31 may comprise one or more of the following combinations;
  • a primer set for analysis of HLA-A * 32 may include one or more of set 3-1, set 6, set 9-1, set 11, set 15-1, set 17.
  • a set of primers for analysis of HLA-A * 32 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-A * 33 includes one or more of set 5-1, set 7-1, set 9-1, set 10-1, set 12-1, set 15-1, set 17 .
  • the set of primers for analysis of HLA-A * 33 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 34 may include one or more of set 7-1, set 9-1, set 13-1, set 15-1, set 17, set 22-1.
  • the set of primers for analysis of HLA-A * 34 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 36 may include one or more of sets 1-1, 15-1, 17.
  • the set of primers for analysis of HLA-A * 36 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 43 can include one or more of set 9-1, set 13-1, set 17.
  • a set of primers for analysis of HLA-A * 36 may comprise set 9-1, set 13-1 and set 17.
  • a primer set for analysis of HLA-A * 66 can include one or more of set 7-1, set 9-1, set 13-1, set 22-1.
  • the set of primers for analysis of HLA-A * 66 may comprise one or more of the following combinations;
  • a primer set for analysis of HLA-A * 68 may include one or more of set 15-1, set 16-1, set 17, set 19-1, set 22-1.
  • the set of primers for analysis of HLA-A * 68 may comprise one or more of the following combinations;
  • a primer set for analysis of HLA-A * 69 can include one or more of set 7-1, set 9-1, set 17, set 18-1, set 22-1.
  • the set of primers for analysis of HLA-A * 69 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 74 may comprise one or more of set 9-1, set 17, set 19-1.
  • the set of primers for analysis of HLA-A * 74 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-A * 80 can include one or more of set 9-1, set 16-1, set 17, set 20-1.
  • the set of primers for analysis of HLA-A * 80 may comprise one or more of the following combinations;
  • the sets may be included in the same well in the test kit, but preferably they may be included in different wells.
  • the wells may include a fluorescent probe to probe the amplified product by real-time PCR.
  • the fluorescent probe can confirm the amplification of the HLA-A allele and can include one or more of the following sequences:
  • SEQ ID NO: 305 FAM 5'-CGTGGATAGAGCAGGAGGGGCCGGAGT-3 'BHQ-1
  • SEQ ID NO: 306 FAM 5'-CGACACGCAGTTCGTGCGGTTCGACAGC-3 'BHQ-1
  • SEQ ID NO: 307 FAM 5'-TGAAGGCCCASTCACAGACTSACCGA-3 'BHQ-1
  • SEQ ID NO: 308 FAM 5'-TGAAGGCCCACTCACAGACTGACCGA-3 'BHQ-1
  • SEQ ID NO: 309 FAM 5'-AGGACCTGCGCTCTTGGACCGCGGCGGAC-3 'BHQ-1
  • SEQ ID NO: 310 FAM 5'-TCTTGGACCGCGGCGGACATGG-3 'BHQ-1
  • the probe of SEQ ID NO: 305 can be combined with set 1-1.
  • the probe of SEQ ID NO: 306 comprises a set 2-1, a set 6-1, a set 8-1, a set 10-1, a set 11-1, a set 12-1, a set 14-1, a set 20-1 , Set 22-1 or set 17, respectively.
  • the probe of SEQ ID NO: 307 can be combined with set 9-1.
  • the probe of SEQ ID NO: 308 can be combined with set 7-1, set 19-1.
  • the probe of SEQ ID NO: 309 comprises a set 3-1, a set 4-1, a set 5-1, a set 13-1, a set 15-1, a set 16-1, a set 18-1, ≪ / RTI >
  • the probe of SEQ ID NO: 310 may be combined with SEQ ID NO:
  • SEQ ID NO: 303 ATGATGTTGACCTTTCCAGGG
  • SEQ ID NO: 304 CTGTAACTTTTCATCAGTTGC
  • SEQ ID NO: 330 Cal-Red610 5'-ACTAACCTCCAACCAACAATCAGC-3 'BHQ2
  • a set of primers for HLA-B gene analysis is set 1-2, set 2-2, set 3-2, set 4-2, set 5-2, set 7-2, set 8-2, set 9-2, Set 10-2, set 12-2, set 13-2, set 14-2, set 15-2, set 16-2, set 18-2, set 19-2, set 20-2, set 21-2, Set 22-2, set 23-2, set 24-2, set 25-2, set 26-2, set 27-2, set 28-2, set 29-2, set 30-2, set 31-2, Set 32-2, set 33-2, set 34-2, set 35-2, set 36-2, set 37-2, set 38-2, set 39-2, set 40-2, set 41-2, A set 42-2, a set 43-2, a set 44-2, a set 45-2, a set 46-2, a set 47, and a set 48.
  • the initial set for analysis of HLA-B * 07 is set 2-2, set 14-2, set 19-2, set 20-2, set 25-2, set 28-2, set 31-2, set 32- 2, set 33-2, set 34-2, set 44-2, set 45-2, set 46-2, set 47, set 48,
  • the set of primers for analysis of HLA-B * 07 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 08 is set 2-2, set 3-2, set 4-2, set 9-2, set 14-2, set 16-2, set 18-2, set 20- 2, set 22-2, set 23-2, set 25-2, set 32-2, set 33-2, set 34-2, set 41-2, set 44-2, set 46-2, set 47, Set 48. < / RTI >
  • the set of primers for analysis of HLA-B * 08 may comprise one or more of the following combinations;
  • Set 2-2 set 3-2, set 20-2, set 44-2 and set 48;
  • Set 3-2 set 4-2, set 14-2, set 33-2, set 44-2 and set 48;
  • the set of primers for the analysis of HLA-B * 13 is set 26-2, set 27-2, set 28-2, set 32-2, set 35-2, set 39-2, set 40-2, set 41- 2, set 45-2, set 47, and the like.
  • the set of primers for analysis of HLA-B * 13 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 14 was set 1-2, set 23-2, set 25-2, set 33-2, set 37-2, set 41-2, set 44-2, set 48 And may include one or more.
  • the set of primers for analysis of HLA-B * 14 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 15 is set 3-2, set 7-2, set 12-2, set 16-2, set 18-2, set 20-2, set 23-2, set 26- 2, set 27-2, set 30-2, set 32-2, set 33-2, set 34-2, set 35-2, set 39-2, set 40-2, set 44-2, set 45- 2, set 47, set 48, and the like.
  • the set of primers for analysis of HLA-B * 15 may comprise one or more of the following combinations;
  • Set 32-2 set 33-2, set 44-2, set 45-2 and set 48;
  • Set 26-2 set 30-2, set 44-2, set 45-2 and set 48;
  • Set 7-2 set 32-2, set 33-2, set 44-2, set 45-2 and set 48;
  • Set 27-2 set 30-2, set 44-2, set 45-2 and set 48;
  • Set 32-2 set 33-2, set 44-2, set 45-2 and set 48;
  • Set 7-2 set 23-2, set 33-2, set 44-2, set 45-2 and set 48;
  • Set 26-2 set 30-2, set 39-2, set 44-2 and set 48;
  • the set of primers for the analysis of HLA-B * 18 is set 1-2, set 4-2, set 7-2, set 13-2, set 20-2, set 28-2, set 29-2, set 33- 2, set 38 - 2, set 44 - 2, set 45 - 2, set 47, set 48.
  • the set of primers for analysis of HLA-B * 18 may comprise one or more of the following combinations;
  • Set 7-2 set 29-2, set 33-2, set 38-2, set 45-2 and set 48;
  • the initial set for analysis of HLA-B * 27 is set 2-2, set 5-2, set 10-2, set 12-2, set 13-2, set 16-2, set 19-2, set 25- 2, set 27-2, set 28-2, set 32-2, set 34-2, set 40-2, set 47, set 48,
  • a set of primers for analysis of HLA-B * 27 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 35 is set 3-2, set 4-2, set 7-2, set 12-2, set 14-2, set 16-2, set 18-2, set 20- 2, set 22-2, set 29-2, set 33-2, set 34-2, set 39-2 set 40-2, set 41-2, set 42-2, set 44-2, set 45-2 , A set 46-2, a set 48, and the like.
  • the set of primers for analysis of HLA-B * 35 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 37 is set 4-2, set 9-2, set 13-2, set 14-2, set 18-2, set 20-2, set 27-2, set 28- 2, set 29 - 2, set 32 - 2, set 33 - 2, set 42 - 2, set 47, set 48.
  • the set of primers for analysis of HLA-B * 37 may comprise one or more of the following combinations;
  • the primer set for analysis of HLA-B * 38 includes one or more of set 4-2, set 23-2, set 25-2, set 28-2, set 32-2, set 42-2, set 47 .
  • the set of primers for analysis of HLA-B * 38 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 39 includes one or more of set 23-2, set 32-2, set 33-2, set 41-2, set 44-2, set 42-2, set 48 .
  • the set of primers for analysis of HLA-B * 39 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 40 is set 2-2, set 13-2, set 16-2, set 18-2, set 19-2, set 21-2, set 27-2, set 32- 2, set 33-2, set 34-2, set 40-2, set 42-2, set 44-2, set 47, set 48,
  • the set of primers for analysis of HLA-B * 40 may comprise one or more of the following combinations;
  • Set 2-2 set 16-2, set 20-2, set 34-2, set 44-2 and set 48;
  • Set 2-2 set 16-2, set 19-2, set 20-2, set 34-2, set 44-2 and set 48;
  • Set 2-2 set 16-2, set 32-2, set 34-2, set 44-2 and set 48;
  • Set 2-2 set 16-2, set 19-2, set 34-2, set 44-2 and set 48;
  • Set 2-2 set 16-2, set 34-2, set 44-2, set 46-2 and set 48;
  • Set 2-2 set 16-2, set 29-2, set 34-2, set 44-2 and set 48;
  • the initial set for analysis of HLA-B * 41 is set 8-2, set 13-2, set 14-2, set 16-2, set 22-2, set 34-2, set 37-2, set 41- 2, set 44-2, set 47, set 48, and the like.
  • the set of primers for analysis of HLA-B * 41 may comprise one or more of the following combinations;
  • Set 8-2 set 16-2, set 34-2, set 37-, set 41-2, set 44-2 and set 48;
  • Set 14-2 set 16-2, set 22-2, set 34-2, set 44-2 and set 48;
  • Set 8-2 set 16-2, set 37-2, set 41-2 and set 48;
  • Set 8-2 set 37-2, set 41-2, set 44-2 and set 48;
  • Set 8-2 set 16-2, set 34-2, set 37-2, set 41-2 and set 44-2;
  • Set 8-2 set 16-2, set 34-2, set 44-2 and set 48;
  • Set 8-2 set 16-2, set 33-2, set 34-2, set 37-2, set 41-2, set 44-2 and set 48;
  • the initial set for analysis of HLA-B * 42 includes one or more of set 2-2, set 14-2, set 20-2, set 25-2, set 32-2, set 33-2, set 48 .
  • the set of primers for analysis of HLA-B * 42 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-B * 44 is set 4-2, set 5-2, set 7-2, set 8-2, set 10-2, set 13-2, set 14-2, set 15- 2, set 16-2, set 18-2, set 20-2, set 21-2, set 22-2, set 27-2, set 29-2, set 32-2, set 34-2, set 35- 2, set 39 - 2, set 40 - 2, set 43 - 2, set 44 - 2, set 45 - 2, set 47, set 48.
  • the set of primers for analysis of HLA-B * 44 may comprise one or more of the following combinations;
  • Set 8-2 set 13-2, set 16-2, set 22-2, set 39-2 and set 47;
  • the initial set for analysis of HLA-B * 45 is set 7-2, set 8-2, set 16-2, set 22-2, set 34-2, set 37-2, set 39-2, set 41- 2, set 44-2, set 45-2, set 46-2, set 48, and the like.
  • the set of primers for analysis of HLA-B * 45 may comprise one or more of the following combinations;
  • Set 8-2 set 16-2, set 22-2, set 34-2, set 39-2, set 44-2 and set 48;
  • Set 8-2 set 16-2, set 22-2, set 34-2, set 44-2 and set 48;
  • Set 8-2 set 16-2, set 22-2, set 34-2, set 39-2, set 44-2, set 46-2 and set 48;
  • Set 8-2 set 16-2, set 22-2, set 34-2, set 37-2, set 41-2, set 44-2 and set 48;
  • Set 8-2 set 16-2, set 34-2, set 39-2, set 44-2 and set 48;
  • a set of primers for analysis of HLA-B * 46 may include one or more of set 7-2, set 24-2, set 39-2, set 41-2, set 44-2, set 45-2, set 48 .
  • the set of primers for analysis of HLA-B * 46 may comprise one or more of the following combinations;
  • Set 7-2 set 24-2, set 44-2, set 45-2 and set 48;
  • a set of primers for analysis of HLA-B * 47 may include one or more of set 16-2, set 18-2, set 34-2, set 44-2, set 47.
  • the set of primers for analysis of HLA-B * 47 may comprise one or more of the following combinations;
  • the set of primers for analysis of HLA-B * 48 is set 2-2, set 19-2, set 20-2, set 28-2, set 32-2, set 33-2, set 44-2, set 45- 2, set 48. < / RTI >
  • the set of primers for analysis of HLA-B * 47 may comprise one or more of the following combinations;
  • the set of primers for analysis of HLA-B * 49 is set 13-2, set 15-2, set 16-2, set 21-2, set 28-2, set 29-2, set 39-2, set 40- 2, set 45-2, set 47, and the like.
  • the set of primers for analysis of HLA-B * 49 may comprise one or more of the following combinations;
  • Set 13-2 set 15-2, set 29-2, set 39-2 and set 47;
  • a set of primers for analysis of HLA-B * 50 is set 12-2, set 16-2, set 34-2, set 37-2, set 39-2, set 40-2, set 41-2, set 44- 2, set 48. < / RTI >
  • the set of primers for analysis of HLA-B * 50 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 51 is set 3-2, set 4-2, set 12-2, set 13-2, set 15-2, set 16-2, set 26-2, set 28- 2, set 35 - 2, set 39 - 2, set 40 - 2, set 41 - 2, set 45 - 2, set 47.
  • the set of primers for analysis of HLA-B * 51 may comprise one or more of the following combinations;
  • Set 3-2 set 4-2, set 15-2, set 40-2 and set 47;
  • the set of primers for analysis of HLA-B * 52 is set 13-2, set 15-2, set 27-2, set 29-2, set 32-3, set 35-2, set 39-2, set 40- 2, set 41-2, set 45-2, set 47, and the like.
  • the set of primers for analysis of HLA-B * 52 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 53 is set 4-2, set 7-2, set 16-2, set 18-2, set 22-2, set 28-2, set 29-2, set 45- 2, and set 47.
  • the set of primers for analysis of HLA-B * 53 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-B * 54 may include one or more of set 31-2, set 39-2, set 41-2, set 44-2, set 45-2, set 46-2.
  • the set of primers for analysis of HLA-B * 54 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 55 was set 25-2, set 26-2, set 31-2, set 32-2, set 41-2, set 44-2, set 46-2, set 48 And may include one or more.
  • the set of primers for analysis of HLA-B * 55 may comprise one or more of the following combinations;
  • the set of primers for analysis of HLA-B * 56 is set 23-2, set 25-2, set 26-2, set 39-2, set 40-2, set 44-2, set 45-2, set 46- 2, set 47, set 48, and the like.
  • the set of primers for analysis of HLA-B * 56 may comprise one or more of the following combinations;
  • the set of primers for the analysis of HLA-B * 57 is set 12-2, set 13-2, set 15-2, set 16-2, set 28-2, set 35-2, set 43-2, set 44- 2, set 45 - 2, set 47, set 48.
  • the set of primers for analysis of HLA-B * 57 may comprise one or more of the following combinations;
  • the set of primers for the analysis of HLA-B * 58 is set 7-2, set 15-2, set 36-2, set 39-2, set 40-2, set 42-2, set 43-2, set 44- 2, set 45-2, set 47, set 48, and the like.
  • the set of primers for analysis of HLA-B * 58 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-B * 59 may include one or more of set 23-2, set 41-2, set 47.
  • the set of primers for analysis of HLA-B * 59 may comprise one or more of the following combinations;
  • a primer set for analysis of HLA-B * 67 can include set 25-2, set 42-2 and set 48.
  • a set of primers for analysis of HLA-B * 73 can include set 48.
  • a set of primers for analysis of HLA-B * 78 may include one or more of set 4-2, set 29-2, set 40-2, set 44-2, set 48.
  • the set of primers for analysis of HLA-B * 78 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-B * 81 may include one or more of set 2-2, set 29-2, set 33-2, set 40-2, set 44-2, set 48.
  • the set of primers for analysis of HLA-B * 81 may comprise one or more of the following combinations;
  • a set of primers for analysis of HLA-B * 82 can consist of sets 22-2, 25-2, 39-2, and 48.
  • a set of primers for analysis of HLA-B * 83 can consist of set 10-2, set 25-2, set 44-2, set 46-2 and set 48.
  • the sets may be included in the same well in the test kit, but preferably they may be included in different wells.
  • the wells may include a fluorescent probe to probe the amplified product by real-time PCR.
  • the fluorescent probe can confirm the amplification of the HLA-B allele and can include one or more of the following sequences:
  • SEQ ID NO: 311 JOE 5'-CAARGATTACATCGCCCTGAACGAGGACC-3 'BHQ-2
  • SEQ ID NO: 312 JOE 5'-AGAGCARGAGGGGCCGGARTATTGGGAC-3 'BHQ-2
  • SEQ ID NO: 314 JOE 5'-TGGAGTGGCTCCGCAGATACCTGGAGAACG-3 'BHQ-2
  • SEQ ID NO: 315 JOE 5'-CGTGAGGTTCGACAGCGACGCCGCGAGTCC-3 'BHQ-2
  • SEQ ID NO: 316 JOE 5'-ACCGTGGGCTACGTGGACGACACGCTGTT-3 'BHQ-2
  • the probe of SEQ ID NO: 311 is set 1-2, set 2-2, set 7-2, set 8-2, set 9-2, set 10-2, set 12-2, set 14-2 Set 19-2, set 22-2, set 37-2, set 39-2, set 40-2, set 41-2, set 42-2, set 43-2, or set 45-2 .
  • the probe of SEQ ID NO: 312 comprises a set 3-2, a set 4-2, a set 5-2, a set 13-2, a set 15-2, a set 18-2, a set 23-2, a set 24-2 Set 25-2, set 26-2, set 27-2, set 28-2, set 29-2, set 30-2, set 31-2, set 32-2, set 33-2, set 34-2 , Set 44-2, set 47-2, or set 48-2.
  • the probe of SEQ ID NO: 313 may be combined with set 16-2 or set 46-2.
  • the probe of SEQ ID NO: 314 can be combined with set 20-2.
  • the probe of SEQ ID NO: 315 can be combined with set 38-2.
  • the probe of SEQ ID NO: 316 can be combined with set 21-2.
  • the well may further include a primer set of SEQ ID NO: 303 and SEQ ID NO: 304, and a fluorescence probe set of SEQ ID NO: 330 to detect the presence or absence of HLA-B amplification.
  • the set of primers for HLA-DRB1 gene analysis was set 23-1, set 24-1, set 25-1, set 26-1, set 27-1, set 28-1, set 29-1, set 30-1, Set 31-1, set 32-1, set 33-1, set 34-1, set 35-1, set 36-1, set 37-1, set 38-1, set 39-1, set 40-1, A set 41-1, a set 42-1, a set 43-1, a set 44-1, a set 45-1, and a set 46-1.
  • a set of primers for analysis of HLA-DRB1 * 01 can be set 23-1.
  • the initial set for analysis of HLA-DRB1 * 03 may include one or more of set 26-1, set 36-1, set 44-1, set 39-1, set 40-1.
  • the set of primers for analysis of HLA-DRB1 * 03 may comprise one or more of the following combinations;
  • the initial set for analysis of HLA-DRB1 * 04 may include one or more of set 27-1, set 45-1, set 41-1, set 38-1.
  • the set of primers for analysis of HLA-DRB1 * 04 may comprise one or more of the following combinations;

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un kit de génotypage d'allèle HLA comprenant : un ensemble d'amorces permettant l'amplification spécifique d'un allèle HLA pour un ou plusieurs gènes sélectionnés parmi HLA-A, HLA-B, HLA-DRB1, HLA-C, HLA-DQB1 et HLA-DQA1 par amplification en chaîne par polymérase en temps réel ; et une sonde capable d'explorer le produit amplifié par l'amplification en chaîne par polymérase en temps réel, et un procédé de détermination d'un allèle HLA l'utilisant.
PCT/KR2018/014407 2017-11-23 2018-11-22 Kit de génotypage hla utilisant une amplification en chaîne par polymérase en temps réel Ceased WO2019103475A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170157699A KR102673550B1 (ko) 2017-11-23 2017-11-23 실시간 중합 효소 연쇄 반응을 이용한 ｈｌａ 대립유전자 검사 키트
KR10-2017-0157699 2017-11-23

Publications (2)

Publication Number Publication Date
WO2019103475A2 true WO2019103475A2 (fr) 2019-05-31
WO2019103475A3 WO2019103475A3 (fr) 2019-07-18

Family

ID=66631596

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/014407 Ceased WO2019103475A2 (fr) 2017-11-23 2018-11-22 Kit de génotypage hla utilisant une amplification en chaîne par polymérase en temps réel

Country Status (2)

Country Link
KR (1) KR102673550B1 (fr)
WO (1) WO2019103475A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102475292B1 (ko) * 2020-09-03 2022-12-08 주식회사 엔젠바이오 Hla 유전자 증폭용 조성물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005063985A1 (fr) * 2003-12-25 2005-07-14 Canon Kabushiki Kaisha Ensemble sonde et procede permettant d'identifier un allele de hla
SG172644A1 (en) * 2006-02-27 2011-07-28 Genomics Usa Population scale hla-typing and uses thereof
KR101252507B1 (ko) * 2009-06-05 2013-04-09 가톨릭대학교 산학협력단 실시간 중합효소연쇄반응을 이용한 ｈｌａ 대립유전자 자동검사 키트
CN103890190B (zh) * 2011-07-21 2016-08-17 吉诺戴夫制药株式会社 Hla基因的dna分型方法和试剂盒
KR101320622B1 (ko) * 2013-03-08 2013-10-23 (주)진스랩 스피드 멀티플렉스 pcr법을 이용한 hla 대립유전자 검사방법 및 검사키트
AU2014355369B2 (en) * 2013-11-27 2020-08-13 Genodive Pharma Inc. Simple method and kit for DNA profiling of HLA genes by high-throughput massively parallel sequencer
KR20160038328A (ko) * 2014-09-30 2016-04-07 윤현규 Hla 유전자를 이용한 실시간 증폭실험 방법
KR101754076B1 (ko) * 2015-10-29 2017-07-05 윤현규 리얼타임 ｐｃｒ을 이용한 ｈｌａ-ｄｒｂ１ 및 ｈｌａ-ｄｒｂ３/４/５ 유전자형 분석 방법 및 키트

Also Published As

Publication number Publication date
KR102673550B1 (ko) 2024-06-12
WO2019103475A3 (fr) 2019-07-18
KR20190059780A (ko) 2019-05-31

Similar Documents

Publication Publication Date Title
WO2018001258A1 (fr) Sonde pour l'enrichissement et la capture d'acides nucléiques, et son procédé de conception
WO2018139826A1 (fr) Procédé de prédiction de l'âge faisant appel à la méthylation de l'adn
WO2017188669A2 (fr) Procédé de détection de séquence d'acide nucléique cible à l'aide d'un fragment de marqueur complémentaire clivé et composition associée
WO2011157222A1 (fr) Méthodes de détection commune de gènes de fusion de lymphome et trousses de diagnostic associées
WO2023191206A1 (fr) Système et procédé d'automatisation d'analyse de données d'exploration sur la base d'attributs variables
WO2015199387A2 (fr) Gène de l'a-1,2 fucosyltransférase d'helicobacter pylori et protéine caractérisée par une expression améliorée d'une protéine soluble, et leur utilisation dans le cadre de la production d'un a-1,2 fucosyloligosaccharide
CN101768639A (zh) 一种甘蓝型油菜品种ssr指纹的快捷检测方法
WO2020105873A1 (fr) Kit de diagnostic et procédé d'identification de séquence complète du génome utilisant l'amplification complète du génome de coronavirus alpha humain
WO2019103475A2 (fr) Kit de génotypage hla utilisant une amplification en chaîne par polymérase en temps réel
WO2017146400A1 (fr) Composé et composition de détection de phosgène et de chlorophosphate de diéthyle
CN100580092C (zh) 用于禽流感病毒检测和分型的基因芯片
WO2020122679A1 (fr) Procédé de détection d'un analyte cible dans un échantillon à l'aide d'une fonction en forme de s pour un ensemble de données de pente
WO2022005023A1 (fr) Organoïde de mésencéphale, son procédé de production rapide en grandes quantités, et procédé de criblage de neurotoxines et procédé de criblage de médicaments pour une maladie associée aux neurones dopaminergiques l'utilisant
WO2014157825A1 (fr) Procédé et trousse d'analyse d'allèles hla utilisant une pcr multiplex rapide
WO2011120398A1 (fr) Procédé de détection conjointe de gènes de fusion de leucémie et trousses de diagnostic
WO2016122058A1 (fr) Procédé permettant l'analyse de l'activité de la phénylalanine hydroxylase à l'aide de myxomycoses cellulaires
WO2022055276A1 (fr) Marqueur de polymorphisme pour les gènes associés à la perte de cheveux chez la femme et son utilisation
WO2014175604A2 (fr) Composition permettant de diagnostiquer la dystrophie cornéenne d'avellino et méthode de diagnostic de la dystrophie cornéenne d'avellino
WO2010140827A9 (fr) Trousse de détection automatique d''allèles hla par réaction en chaîne de la polymérase en temps réel
WO2015167087A1 (fr) Procédé pour prédire le risque d'une spondylarthrite ankylosante à l'aide de variants du nombre de copies d'adn
WO2019022520A1 (fr) Paire de complexes d'acide nucléique, structure compétitive et kit de pcr utilisant les deux
WO2019135477A2 (fr) Procédé de diagnostic de maladie de tsutsugamushi au moyen de gène multicopie
WO2024136591A1 (fr) Identification et diagnostic de résistance de mycobacterium tuberculosis et d'une infection mycobactérienne non tuberculeuse à l'aide d'un séquençage nouvelle génération
WO2025143555A1 (fr) Procédé de détection d'analyte cible dans un échantillon
WO2024242531A2 (fr) Ensemble de sondes de capture pour la détection simultanée d'un virus et de bactéries sur la base du syndrome de typhus murin, son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18880696

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18880696

Country of ref document: EP

Kind code of ref document: A2